Personally I'd like to see the PR out tomorrow

New Post Public Reply Private Reply Replies (2) Message Board
MUKA1
Personally I'd like to see the PR out tomorrow before/during trading. This will provide pps pop even with those selling on news it would continue the upward movement. Would also provide some media leading into #C4CT coverage.

Then, when the typical AMBS conference day dip begins, another PR with additional information to be discussed by Kirby and Arendt to once again catch the flippers/shorters and keep the momentum going. This could be any number of the items we are waiting to hear about. (Grant apps, partner, date of revenue projections.)

Amarantus Bioscience Holdings (AMBS) Stock Research Links

AMBS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Exploring the $2.7 Billion Bid for Papa John’s: An Investment Insight

Updated Category News Views 229

Papa John’s $2.7 Billion Takeover Bid: Insights into Potential Value Recently, shares of Papa John’s International Inc (NASDAQ:PZZA) experienced a notable surge, leading to a halt in trading due to high volatility. This surprising movement came in light of credible reports suggesting a take-private cash offer of $65 per share from TriArtisan Capital Advisors, totaling...

Continue Reading
Key Highlights from Octopus Apollo VCT plc AGM Results

Updated Category News Views 105

Octopus Apollo VCT plc AGM Results Overview Octopus Apollo VCT plc recently conducted its Annual General Meeting (AGM), showcasing significant engagement from shareholders. The meeting aimed to discuss key resolutions impacting the future direction of the company. Voting Outcomes of the AGM The company disclosed that all resolutions were successfully passed during the...

Continue Reading
Carisma Therapeutics Showcases Strong Financial Performance

Updated Category News Views 104

Carisma Therapeutics Showcases Strong Financial Performance Carisma Therapeutics Inc. (NASDAQ: CARM), a clinical-stage biopharmaceutical company, recently released its financial performance for the third quarter of 2024. With a focus on developing innovative immunotherapies, Carisma provided insight into its ongoing projects. Key Developments and Milestones Carisma's...

Continue Reading
Epinephrine Market Growth Insights and Future Potential

Updated Category News Views 112

Overview of the Epinephrine Market The global epinephrine market is on a significant upswing, with recent evaluations estimating its value at USD 3.11 billion and a projected growth to approximately USD 6.39 billion within the next decade. As a critical hormone and neurotransmitter produced by the adrenal glands, epinephrine is essential in treating severe allergic...

Continue Reading
Canadian North Resources Achieves Major Milestones in Q2 2025

Updated Category News Views 183

Canadian North Resources Makes Significant Progress in Operational Strategy Highlights: Canadian North has expanded its bio-metallurgical programs significantly, achieving impressive nickel and cobalt extraction rates through innovative bio-leaching tests. The focus remains on extracting copper and other precious group elements (PGE) metals from the Ferguson Lake Project....

Continue Reading